Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...
Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...
Today, the Council added two countries - Turks and Caicos Islands and Viet Nam – to the EU list. At the same time, three countries - Fiji, Samoa and Trinidad and Tobago - were removed. Following this ...
For about one-third of people, a new episode of low back pain will recover in around two weeks. However, for about 10 per ...
Introduction Atrial fibrillation (AF), with a prevalence of 1–2%, is the most common cardiac arrhythmia. AF is associated with a fivefold increased risk of cardioembolic events; approximately 20% of ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...
Background Motor and cognitive dysfunctions are common and disabling features in multiple sclerosis (MS) that remain challenging to treat. Here, we aimed to explore the effect of exergames as a ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today provided recent business highlights and reported ...
New study findings show that utilizing super-high-pressure non-compliant balloons (NCB) is non-inferior to intravascular lithotripsy (IVL) balloon catheters for lesion preparation and stent expansion ...
Background Non-inferiority (NI) studies with mortality end points are increasingly frequently conducted. They aim to show that a new treatment strategy does not entail an unacceptably higher mortality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results